| Contents | 6 |
|---|
| Contributors | 8 |
|---|
| 1 Sepsis: Introduction and Epidemiology | 10 |
|---|
| The Epidemiology of Sepsis | 10 |
| Incidence and Occurrence of Sepsis | 11 |
| Outcome from Sepsis | 12 |
| Predictors of Outcome | 12 |
| Changes in Microbiology Over Time | 13 |
| The Economics of Sepsis | 13 |
| Conclusion | 13 |
| References | 13 |
| 2 Mechanisms of Innate Immunity in Sepsis | 14 |
|---|
| The Innate Immune Response in Sepsis | 14 |
| Triggering of Innate Immune Responses | 15 |
| Toll-Like Receptors | 15 |
| TLR Signaling | 16 |
| Regulation of TLR Signaling | 18 |
| Endotoxin Tolerance | 18 |
| Clinical Directions | 19 |
| References | 19 |
| 3 Metabolic and Endocrine Changes in Sepsis and the Catabolic State | 20 |
|---|
| Sepsis and the Catabolic State | 20 |
| Metabolic-Nutritional Responses to Sepsis and Critical Illness | 20 |
| The Insulin-Glucose Axis in Sepsis and Critical Illness | 21 |
| Endocrine Responses to Sepsis and Critical Illness | 21 |
| Implications for Clinical Practice | 24 |
| 4 Hematological and Coagulation Changes in Sepsis | 26 |
|---|
| Introduction | 26 |
| Hematological Changes in Sepsis | 26 |
| Coagulation Changes in Sepsis | 28 |
| Disseminated Intravascular Coagulation | 28 |
| Other Coagulation Changes in Sepsis | 32 |
| Conclusion | 32 |
| References | 33 |
| 5 The Genetics of Sepsis and Inflammation | 35 |
|---|
| What Are Genetic Polymorphisms and How Can They Be Used to Investigate the Genetics of Sepsis? | 35 |
| Genetic Association Studies in Sepsis | 37 |
| Combinations of Polymorphisms | 39 |
| Clinical Uses for Polymorphisms | 39 |
| The Future | 39 |
| 6 Cardiac, Circulatory, and Microvascular Changes in Sepsis and Multiorgan Dysfunction Syndrome | 41 |
|---|
| Cardiovascular Effects of Sepsis | 41 |
| Cardiovascular Support in Sepsis | 44 |
| Microcirculation and Cellular Considerations in Sepsis | 45 |
| Summary | 47 |
| References | 47 |
| 7 Specific Bacterial Infections in the Immunocompetent Patient | 49 |
|---|
| Meningococcal Disease | 49 |
| b-Hemolytic Streptococci | 51 |
| Toxic Shock Syndrome | 52 |
| Surgical Infections | 54 |
| 8 Infection in the Immunocompromised Patient | 56 |
|---|
| Increased Susceptibility to Infection | 56 |
| Management of Granulocytopenic Sepsis | 58 |
| Humoral Immunodeficiency | 60 |
| CMV Infection in Transplant Recipients | 60 |
| Pneumocystis Jiroveci Pneumonia | 62 |
| Diagnosis | 63 |
| 9 Severe Infections in the Returning Traveler | 65 |
|---|
| Severe and Complicated Malaria | 65 |
| SARS as an Example of an Emerging Contagious Disease with High Morbidity and Mortality | 67 |
| Viral Hemorrhagic Fever | 69 |
| Summary | 71 |
| 10 Antibiotic Prescribing Including Antibiotic Resistance | 72 |
|---|
| Important Antibiotics and their Use in the Critical Care Setting | 72 |
| Principles of Choice of Antimicrobial Agent | 74 |
| Principles for Prescribing Antimicrobial Agents | 74 |
| Antibiotic Resistance | 76 |
| Current Therapeutic Problems in ITU | 77 |
| Summary | 78 |
| 11 Infection Control in the Intensive Care Unit | 79 |
|---|
| General Principles | 79 |
| Means of Transmission of Infection | 79 |
| Patient Isolation | 80 |
| Universal Precautions | 80 |
| Specific Problems | 81 |
| Conclusions | 85 |
| 12 Randomized Controlled Trials in Sepsis | 87 |
|---|
| Management of the Proinflammatory Response | 87 |
| Management of the Metabolic Response | 89 |
| Management of the Procoagulant Response | 90 |
| Standard Resuscitation | 92 |
| Conclusions | 94 |
| 13 Guidelines, Protocols, and the Surviving Sepsis Guidelines: A Critical Appraisal | 96 |
|---|
| What is the Purpose of Guidelines? | 96 |
| Why do Guidelines Fail? | 96 |
| Conclusion | 100 |
| 14 Practical Approaches to the Patient with Severe Sepsis: Illustrative Case Histories | 102 |
|---|
| Illustrative Cases | 103 |
| Practical Tips and Avoiding Pitfalls | 106 |
| Conclusions | 107 |
| References | 107 |
| Index | 108 |